mBio (Feb 2023)

A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies

  • Frederic Bibollet-Ruche,
  • Ronnie M. Russell,
  • Wenge Ding,
  • Weimin Liu,
  • Yingying Li,
  • Kshitij Wagh,
  • Daniel Wrapp,
  • Rumi Habib,
  • Ashwin N. Skelly,
  • Ryan S. Roark,
  • Scott Sherrill-Mix,
  • Shuyi Wang,
  • Juliette Rando,
  • Emily Lindemuth,
  • Kendra Cruickshank,
  • Younghoon Park,
  • Rachel Baum,
  • John W. Carey,
  • Andrew Jesse Connell,
  • Hui Li,
  • Elena E. Giorgi,
  • Ge S. Song,
  • Shilei Ding,
  • Andrés Finzi,
  • Amanda Newman,
  • Giovanna E. Hernandez,
  • Emily Machiele,
  • Derek W. Cain,
  • Katayoun Mansouri,
  • Mark G. Lewis,
  • David C. Montefiori,
  • Kevin J. Wiehe,
  • S. Munir Alam,
  • I-Ting Teng,
  • Peter D. Kwong,
  • Raiees Andrabi,
  • Laurent Verkoczy,
  • Dennis R. Burton,
  • Bette T. Korber,
  • Kevin O. Saunders,
  • Barton F. Haynes,
  • Robert J. Edwards,
  • George M. Shaw,
  • Beatrice H. Hahn

DOI
https://doi.org/10.1128/mbio.03370-22
Journal volume & issue
Vol. 14, no. 1

Abstract

Read online

ABSTRACT HIV-1 and its SIV precursors share a broadly neutralizing antibody (bNAb) epitope in variable loop 2 (V2) at the envelope glycoprotein (Env) trimer apex. Here, we tested the immunogenicity of germ line-targeting versions of a chimpanzee SIV (SIVcpz) Env in human V2-apex bNAb heavy-chain precursor-expressing knock-in mice and as chimeric simian-chimpanzee immunodeficiency viruses (SCIVs) in rhesus macaques (RMs). Trimer immunization of knock-in mice induced V2-directed NAbs, indicating activation of V2-apex bNAb precursor-expressing mouse B cells. SCIV infection of RMs elicited high-titer viremia, potent autologous tier 2 neutralizing antibodies, and rapid sequence escape in the canonical V2-apex epitope. Six of seven animals also developed low-titer heterologous plasma breadth that mapped to the V2-apex. Antibody cloning from two of these animals identified multiple expanded lineages with long heavy chain third complementarity determining regions that cross-neutralized as many as 7 of 19 primary HIV-1 strains, but with low potency. Negative stain electron microscopy (NSEM) of members of the two most cross-reactive lineages confirmed V2 targeting but identified an angle of approach distinct from prototypical V2-apex bNAbs, with antibody binding either requiring or inducing an occluded-open trimer. Probing with conformation-sensitive, nonneutralizing antibodies revealed that SCIV-expressed, but not wild-type SIVcpz Envs, as well as a subset of primary HIV-1 Envs, preferentially adopted a more open trimeric state. These results reveal the existence of a cryptic V2 epitope that is exposed in occluded-open SIVcpz and HIV-1 Env trimers and elicits cross-neutralizing responses of limited breadth and potency. IMPORTANCE An effective HIV-1 vaccination strategy will need to stimulate rare precursor B cells of multiple bNAb lineages and affinity mature them along desired pathways. Here, we searched for V2-apex germ line-targeting Envs among a large set of diverse primate lentiviruses and identified minimally modified versions of one chimpanzee SIV Env that bound several human V2-apex bNAb precursors and stimulated one of these in a V2-apex bNAb precursor-expressing knock-in mouse. We also generated chimeric simian-chimpanzee immunodeficiency viruses and showed that they elicit low-titer V2-directed heterologous plasma breadth in six of seven infected rhesus macaques. Characterization of this antibody response identified a new class of weakly cross-reactive neutralizing antibodies that target the V2-apex, but only in occluded-open Env trimers. The existence of this cryptic epitope, which in some Env backgrounds is immunodominant, needs to be considered in immunogen design.

Keywords